Evaluation of strategies to increase efficacy and prevent relapse with IDH inhibitors are ongoing, including clinical investigations of treatment combinations with standard anti-leukemia therapies (i.e., intensive chemotherapy, hypomethylating agents) as well as rational combinations (venetoclax) and agents targeted against AML resistance pathways (i.e., FLT3, RAS, other RTK pathway inhibitors). Here, FLT3 is linked to acute myeloid leukemia.